N Engl J Med 380(24):22952306 Kristensen SL, Rrth R, Jhund PS, Docherty KF, Sattar N, Preiss D et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Cardiovascular risk and obesity
Those whose carnitine levels may be impacted by aging, certain medications, liver function, or metabolic factors may particularly benefit from dual-form supplementation.* Practitioner Reference Carnitine Synergy is positioned within the Designs for Health Cardiovascular Health category
Seek medical attention immediately if you develop severe vomiting, dehydration, chest pain, difficulty breathing, severe abdominal pain, or signs of low blood sugar while using GLP-1 medications
Solutions for Joint Pain with GLOW Peptide Therapy: Tendons and ligaments are notoriously slow healers due to poor blood supply
The delta EEG (sleep)-inducing peptide (DSIP)